The Health Ministry in India has recommended that a compulsory licence (CL) is issued for the manufacture of Bristol-Myers Squibb’s (BMS) anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
To request a FREE 2-week trial subscription, use the same link but select the 'trial' option in the dropdown box. NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org
Sprycel, India, Patent, WTO TRIPS, Compulsory Licence,